Clinical Trial Highlights

• DECIDE: Significantly Improved Brain MRI Results with DAC HYP versus Interferon in RRMS
• ADVANCE Results: PEG-IFN-β-1a Decreases Disability in RRMS
• ADVANCE Trial: PEG-IFN-β-1a Every 2 Weeks Significantly Improved Outcomes over 2 Years in RRMS
• BRAVO Analysis: Laquinimod Reduces Brain Atrophy in Patients with RRMS
• FACTSEP Results: L-carnitine Not Effective for Treatment of Fatigue in MS Patients
• CARE-MS II Follow-up: Improvements with Alemtuzumab Maintained for 4 Years
• CARE-MS I Follow-up: Alemtuzumab Efficacy, Safety for MS Treatment Maintained for More than 4 Years
• RPC1063 Safe and Effective in RRMS
• GATE: Generic GA as Effective and Safe as Copaxone for Patients with RRMS
• Postrelapse MS Treatment with Alemtuzumab Better than SC IFN-β-1a
• Results of DECIDE: DAC HYP Superior to IFN-β-1a for RRMS
• HspB5 Improves MRI Lesions and Clinical Relapse in RRMS
• PR—Fampridine Improves Mobility in Patients with MS
• Improvement in UI with OnabotulinumtoxinA Maintained over 4 Years in Patients with MS
• Potential Genetic Locus Associated with MS Identified in African Americans